JP2010532340A5 - - Google Patents

Download PDF

Info

Publication number
JP2010532340A5
JP2010532340A5 JP2010514144A JP2010514144A JP2010532340A5 JP 2010532340 A5 JP2010532340 A5 JP 2010532340A5 JP 2010514144 A JP2010514144 A JP 2010514144A JP 2010514144 A JP2010514144 A JP 2010514144A JP 2010532340 A5 JP2010532340 A5 JP 2010532340A5
Authority
JP
Japan
Prior art keywords
formula
compound
compounds
present
examples
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010514144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010532340A (ja
JP5368438B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2008/050525 external-priority patent/WO2009004379A1/en
Publication of JP2010532340A publication Critical patent/JP2010532340A/ja
Publication of JP2010532340A5 publication Critical patent/JP2010532340A5/ja
Application granted granted Critical
Publication of JP5368438B2 publication Critical patent/JP5368438B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010514144A 2007-07-05 2008-07-01 新規化合物951:crth2モジュレーターとしてのビフェニルオキシプロパン酸および中間体 Expired - Fee Related JP5368438B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94801207P 2007-07-05 2007-07-05
US60/948,012 2007-07-05
PCT/GB2008/050525 WO2009004379A1 (en) 2007-07-05 2008-07-01 Novel compounds 951: a biphenyloxypropanoic acid as crth2 modulator and intermediates

Publications (3)

Publication Number Publication Date
JP2010532340A JP2010532340A (ja) 2010-10-07
JP2010532340A5 true JP2010532340A5 (enExample) 2011-07-28
JP5368438B2 JP5368438B2 (ja) 2013-12-18

Family

ID=39942682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010514144A Expired - Fee Related JP5368438B2 (ja) 2007-07-05 2008-07-01 新規化合物951:crth2モジュレーターとしてのビフェニルオキシプロパン酸および中間体

Country Status (29)

Country Link
US (1) US8507544B2 (enExample)
EP (1) EP2173730B1 (enExample)
JP (1) JP5368438B2 (enExample)
KR (1) KR20100039326A (enExample)
CN (1) CN101796042B (enExample)
AR (1) AR067461A1 (enExample)
AU (1) AU2008272690B2 (enExample)
BR (1) BRPI0813992A2 (enExample)
CA (1) CA2691615A1 (enExample)
CL (1) CL2008001982A1 (enExample)
CO (1) CO6270211A2 (enExample)
CY (1) CY1114804T1 (enExample)
DK (1) DK2173730T3 (enExample)
EC (1) ECSP109848A (enExample)
ES (1) ES2442523T3 (enExample)
HR (1) HRP20140004T1 (enExample)
MY (1) MY153957A (enExample)
NZ (1) NZ582192A (enExample)
PE (2) PE20090475A1 (enExample)
PL (1) PL2173730T3 (enExample)
PT (1) PT2173730E (enExample)
RS (1) RS53129B (enExample)
SA (1) SA08290406B1 (enExample)
SI (1) SI2173730T1 (enExample)
TW (1) TWI453017B (enExample)
UA (1) UA100983C2 (enExample)
UY (1) UY31208A1 (enExample)
WO (1) WO2009004379A1 (enExample)
ZA (1) ZA200909226B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301009D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
GB0415320D0 (en) * 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
ATE517085T1 (de) 2004-11-23 2011-08-15 Astrazeneca Ab Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
EP1937632A1 (en) 2005-10-06 2008-07-02 Astra Zeneca AB Novel compounds
WO2007052023A2 (en) * 2005-11-05 2007-05-10 Astrazeneca Ab Novel compounds
WO2007068894A2 (en) * 2005-12-15 2007-06-21 Astrazeneca Ab Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
EP2257524B1 (en) 2008-02-01 2016-01-06 Brickell Biotech, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
EP2245022A4 (en) 2008-02-25 2012-02-22 Panmira Pharmaceuticals Llc ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
US8378107B2 (en) 2008-10-01 2013-02-19 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
SG178109A1 (en) 2009-07-31 2012-03-29 Panmira Pharmaceuticals Llc Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
KR20120047273A (ko) 2009-08-05 2012-05-11 판미라 파마슈티칼스, 엘엘씨 Dp2 길항제 및 이의 용도
ES2553871T3 (es) 2010-07-05 2015-12-14 Actelion Pharmaceuticals Ltd. Derivados heterociclilo 1-fenil-sustituidos y su uso como moduladores del receptor D2 de prostaglandina
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
AU2012356076A1 (en) 2011-12-21 2014-08-14 Actelion Pharmaceuticals Ltd Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
US9169270B2 (en) 2012-07-05 2015-10-27 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
KR101538846B1 (ko) 2013-07-30 2015-07-22 동아에스티 주식회사 신규한 바이페닐 유도체 및 그의 제조방법

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278524A (en) 1962-03-13 1966-10-11 Beecham Group Ltd Penicillins and their production
CH432119A (de) 1963-02-22 1967-03-15 Geigy Ag J R Verwendung von Halogen-o-hydroxy-diphenyläthern als antimikrobielle Mittel
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
DD113545A5 (enExample) 1973-03-30 1975-06-12
JPS5239888B2 (enExample) 1973-05-28 1977-10-07
CH582476A5 (enExample) 1973-10-29 1976-12-15 Ciba Geigy Ag
GB1585963A (en) 1976-10-14 1981-03-11 Lilly Industries Ltd Aryl sulphur compounds
JPS5951943B2 (ja) 1978-08-21 1984-12-17 キツセイ薬品工業株式会社 新規なイミダゾ−ル誘導体
GB2041363B (en) 1979-01-19 1982-10-06 Pfizer Ltd N-benzyl-imidazoles
US4670566A (en) 1979-07-12 1987-06-02 A. H. Robins Company, Incorporated 3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones
US4486593A (en) 1983-01-19 1984-12-04 The Upjohn Company 2-,3-, or 4-Pyridinylmethylamino arylic acids as thromboxane A2 synthetase and 5-lipoxygenase inhibitors
US5006542A (en) 1988-10-31 1991-04-09 E. R. Squibb & Sons, Inc. Arylthioalkylphenyl carboxylic acids, derivatives thereof, compositions containing same and method of use
US5145790A (en) 1990-05-04 1992-09-08 Abbott Laboratories Reagents and method for detecting polychlorinated biphenyls
EP0540165A1 (en) 1991-10-03 1993-05-05 Zeneca Limited Alkanoic acid derivatives
WO1993012086A1 (fr) 1991-12-11 1993-06-24 Ss Pharmaceutical Co., Ltd. Derive d'arylamide
CA2090283A1 (en) 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
EP0607536B1 (en) 1992-12-08 2001-01-24 Ss Pharmaceutical Co., Ltd. Arylamide derivatives
JPH06313995A (ja) 1993-04-28 1994-11-08 Hodogaya Chem Co Ltd 静電荷像現像用トナー
JPH07140725A (ja) 1993-06-25 1995-06-02 Hodogaya Chem Co Ltd 負帯電性トナー用摩擦帯電付与部材
JPH11512095A (ja) 1995-08-28 1999-10-19 アメリカン・ホーム・プロダクツ・コーポレイション アルドース還元酵素阻害薬および抗高血糖症薬としてのフェノキシ酢酸
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CA2219269A1 (en) 1996-10-29 1998-04-29 Novartis Ag Novel herbicides
FR2763588B1 (fr) 1997-05-23 1999-07-09 Cird Galderma Composes triaromatiques, compositions les contenant et utilisations
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US5942532A (en) 1997-09-05 1999-08-24 Ortho Pharmaceutical Corporation 2-substituted phenyl-benzimidazole antibacterial agents
JP4290872B2 (ja) 1997-09-12 2009-07-08 メルク フロスト カナダ リミテツド シクロオキシゲナーゼ−2阻害薬としての2,3,5−トリ置換ピリジン類
CA2304713C (en) 1997-10-14 2003-06-10 Asahi Kasei Kogyo Kabushiki Kaisha Biphenyl-5-alkanoic acid derivatives and use thereof
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
WO2001014882A1 (fr) 1999-08-23 2001-03-01 Bml, Inc. Identification des proprietes d'une substance pour les recepteurs de prostaglandine d
PT1206457E (pt) 1999-08-27 2004-03-31 Lilly Co Eli Derivados de diaril-oxa(tia)zol e seu uso como moduladores dos ppars
AU784722B2 (en) 2000-02-18 2006-06-01 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
EP1278734A2 (en) 2000-04-24 2003-01-29 Merck Frosst Canada & Co. Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
CA2406979A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
US6699997B2 (en) 2000-06-28 2004-03-02 Teva Pharmaceutical Industries Ltd. Carvedilol
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
CZ200331A3 (cs) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Deriváty kolchinolu jako inhibitory angiogeneze, způsob jejich přípravy a farmaceutická kompozice, která je obsahuje
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
US20040097555A1 (en) 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
US7067507B2 (en) 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
DK1501826T3 (da) 2002-02-01 2007-01-29 Hoffmann La Roche Substituerede indoler som alpha-1-agonister
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
WO2003068744A1 (en) 2002-02-18 2003-08-21 Ishihara Sangyo Kaisha, Ltd. Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same
CA2479338A1 (en) 2002-03-20 2003-10-02 Metabolex, Inc. Substituted phenylacetic acids
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
AR042206A1 (es) 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
EA011087B1 (ru) 2002-12-20 2008-12-30 Эмджен Инк. Соединения и фармацевтические композиции для лечения воспалительных заболеваний
AU2004232682B2 (en) 2003-03-28 2006-12-07 Eli Lilly And Company Isoquinoline-5-sulfonic acid amides as inhibitors of Akt (protein kinase B)
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301009D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
ES2257616T3 (es) 2003-04-25 2006-08-01 Actimis Pharmaceuticals, Inc. Derivados del acido pirimidinilacetico utiles para el tratamiento de enfermedades mediadas por crth2.
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
GB0409921D0 (en) 2004-05-04 2004-06-09 Novartis Ag Organic compounds
JP2008500991A (ja) 2004-05-29 2008-01-17 7ティーエム ファーマ エイ/エス 医学的使用のためのcrth2レセプターリガンド
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
ATE517085T1 (de) 2004-11-23 2011-08-15 Astrazeneca Ab Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
GB0510584D0 (en) 2005-05-24 2005-06-29 Novartis Ag Organic compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
EP1937632A1 (en) 2005-10-06 2008-07-02 Astra Zeneca AB Novel compounds
WO2007052023A2 (en) 2005-11-05 2007-05-10 Astrazeneca Ab Novel compounds
WO2007068894A2 (en) 2005-12-15 2007-06-21 Astrazeneca Ab Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты

Similar Documents

Publication Publication Date Title
JP2010532340A5 (enExample)
EP3077404B1 (en) Purification of tenofovir alafenamide and its intermediates
JP2022043078A5 (enExample)
JP2018529687A5 (enExample)
JP2003528828A5 (enExample)
JP2010174033A5 (enExample)
CA2635917C (en) Method for producing fluorinated organic compounds
JP2013533291A5 (enExample)
JP2010540477A5 (enExample)
RU2010146299A (ru) Способ получения производных 1-(2-галогенобифенил-4-ил)-циклопропанкарбоновой кислоты
MA29464B1 (fr) Methode de preparation d'acides 1,6-dihydro-6-oxo-4-pyrimidinecarboxyliques eventuellement 2-substitues
JP2014510746A5 (enExample)
WO2010024930A3 (en) Cortistatin analogues and syntheses therof
UA99447C2 (ru) Способ получения силденафила
JP2010529994A5 (enExample)
ATE299144T1 (de) Verfahren zur herstellung einer pharmazeutisch aktiven verbindung (granisetron)
JP2008526897A5 (enExample)
US20100029945A1 (en) Process for the purification of Montelukast
JP2008540628A5 (enExample)
ATE441627T1 (de) Verfahren zur herstellung von valsartan
JP6423936B2 (ja) 放射ヨウ素標識された3−フルオロプロピル−NOR−β−CITの調製
WO2007049295B1 (en) An improved one pot process for making key intermediate for gemcitabine hcl
KR20170113590A (ko) 2-((2-에톡시-2-옥소에틸)(메틸)아미노)-2-옥소에틸 5-테트라데실옥시)푸란-2-카르복실레이트의 제조를 위한 합성 방법
JP2013529223A (ja) ピタバスタチンまたはその塩の中間体の製造方法
JP2011503175A5 (enExample)